GILEAD SCIENCES INC
(NASDAQ: GILD)

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

65.480 s

+0.280 (+0.43%)
Range 64.970 - 65.889   (1.41%)
Open -
Previous Close 65.200
Bid Price 78.630
Bid Volume 8
Ask Price 78.820
Ask Volume 8
Volume 7,231,849
Value -
Remark s
Delayed prices. Updated at 02 May 2024 03:59.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Dividend

Ex-Date 14 June 2024
Record Date 14 June 2024
Payable Date 27 June 2024
Ordinary Shares. Amount: USD0.77
View All Events

About GILEAD SCIENCES INC

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

Loading Chart...

Please login to view stock data and analysis